Agios Reports Business Highlights and Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Agios Pharma (AGIO) Misses Q3 EPS by 1c
October 31, 2019 7:08 AM EDTAgios Pharma (NASDAQ: AGIO) reported Q3 EPS of ($1.81), $0.01 worse than the analyst estimate of ($1.80). Revenue for the quarter came in at $26 million versus the consensus estimate of $35.15 million.
The third quarter was marked by strong commercial execution, now a full year... More
